摘要
目的探讨多药耐药基因蛋白P-糖蛋白(P-gp)、谷胱甘肽-S-转移酶-π(GST-π)及DNA拓扑异构酶Ⅱ(TopoⅡ)在乳腺癌中的表达及其临床意义。方法用免疫组化法检测52例未经抗肿瘤治疗的原发乳腺癌中P-gp、GST-π及TopoⅡ的表达水平。结果52例乳腺癌组织中P-gp、GST-π和TopoⅡ表达率分别为57.7%、53.8%和76.9%,P-gp、GST-π和TopoⅡ的表达与组织学类型、年龄无关(P>0.05),与临床分期、淋巴结转移有显著性差异(P<0.05),P-gp和GST-π的表达呈显著正相关(P<0.05),P-gp和TopoⅡ的表达呈明显负相关(P<0.05),GST-π和TopoⅡ呈明显负相关(P<0.05)。结论乳腺癌化疗前检测P-gp、GST-π及TOPOⅡ耐药基因蛋白,对肿瘤的化疗药物选择及判断预后有一定的价值。
Objective To explore the expression and clinical significance of P-giycoprotein（P-gp）, Glutathione- s- transferase -π（GST-π） and Topo Ⅱ in breast carcinoma tissue. Methods The expression level of P-gtycoprotein （P-gp）, Glutathione- s-transferase - π（GST-π）and Topo Ⅱ in the operating samples from 52 cases with with untreated primary breast carcinomas were detected with immunohistochemical method. Results Positive expression rates of P-gp, GST-π and Topo Ⅱin 52 cases of hreast carcinoma were 57.7%（30/52）, 53.8 % （28/52） and 76.9 % （40/52）. The positive expression of P - gp, GST-π and Topo Ⅱ was no relationship with histological type and patients＇ age （ P 〈 0.05 ）, and which was significant associated with dinical stage and lymph node metasis（ P 〈 0.05） . P - gp significantly positively correlation with GST-π（ P 〈0.05）, P-gp negativdy related to Topo Ⅱ （ P 〈0.05）, GST- π had obvionsly negative corrdation with Topo Ⅱ （ P 〈 0.05）. Conclusion Before chemotherapy to patients with breast carcinoma, the test of resistance drug gene will help doctors select the mechanisms of drug and to evaluate prngnosis of breast carcinoma.
出处
《宁夏医学杂志》
CAS
2006年第7期489-491,F0002,共4页
Ningxia Medical Journal
